Reference health
A Review of Direct Oral Anticoagulants in Patients With Stage 5 or End-Stage Kidney Disease
45/45 checkable references clean · checked 2026-08-10
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
7 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 45 checked references that resolve
resolves10.1161/CIR.0000000000000665
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons
resolves10.1093/eurheartj/ehw210
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
resolves10.1093/eurheartj/ehy136
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
resolves10.1007/s13318-018-0501-y
Clinical Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Patients with Renal Failure
resolves10.1159/000445328
Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis
resolves10.1002/jcph.628
Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis
resolves10.1053/j.ajkd.2017.08.003
Oral Anticoagulants to Prevent Stroke in Nonvalvular Atrial Fibrillation in Patients With CKD Stage 5D: An NKF-KDOQI Controversies Report
resolves10.1038/ki.2011.223
Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)
resolves10.1378/chest.09-1584
Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach
resolves10.1016/j.ahj.2010.03.027
Chronic kidney disease and prevalent atrial fibrillation: The Chronic Renal Insufficiency Cohort (CRIC)
resolves10.1016/j.kint.2018.05.005
Chronic kidney disease and arrhythmias: highlights from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
resolves10.1378/chest.15-1719
Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease
resolves10.1016/j.cjca.2017.02.004
Warfarin and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation Receiving Dialysis: A Systematic Review and Meta-analysis
resolves10.1136/openhrt-2016-000441
Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis
resolves10.1001/jamanetworkopen.2020.2175
Association Between Use of Warfarin for Atrial Fibrillation and Outcomes Among Patients With End-Stage Renal Disease
resolves10.1186/s12882-016-0368-6
Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis
resolves10.1016/j.ahj.2016.09.016
Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis
resolves10.1681/ASN.2008070802
Kidney Function Influences Warfarin Responsiveness and Hemorrhagic Complications
resolves10.1097/MCP.0b013e32832ee371
Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms
resolves10.1111/jth.12652
Kidney disease and risk of venous thromboembolism: a nationwide population‐based case‐control study
resolves10.1371/journal.pone.0249940
Effectiveness and safety of rivaroxaban versus warfarin in Taiwanese patients with end-stage renal disease and nonvalvular atrial fibrillation: A real-world nationwide cohort study
resolves10.1681/ASN.2019060579
Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study
resolves10.1681/ASN.2020111566
Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial
resolves10.1111/ejh.13599
Safety of apixaban compared to warfarin in hemodialysis patients: Do antiplatelets make a difference?
resolves10.1007/s10557-020-07108-4
Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis
resolves10.1177/1060028019897053
Characterizing the Safety Profile of Apixaban Versus Warfarin in Moderate to Severe Chronic Kidney Disease at a Veterans Affairs Hospital
resolves10.1161/CIRCULATIONAHA.118.035418
Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States
resolves10.1002/rth2.12083
Safety and effectiveness of apixaban compared to warfarin in dialysis patients
resolves10.1177/1060028017694654
Safety Outcomes of Apixaban Compared With Warfarin in Patients With End-Stage Renal Disease
resolves10.1111/ejh.13383
Rivaroxaban versus apixaban in non‐valvular atrial fibrillation patients with end‐stage renal disease or receiving dialysis
resolves10.1002/jcph.335
An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis
resolves10.1111/ejh.13208
The efficacy and safety of direct oral anticoagulants in patients with chronic renal insufficiency: A review of the literature
resolves10.1160/th14-06-0547
Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis
The 7 references without a DOI — listed, not checked
no DOI — not checkedCoumadin. Package insert. Bristol-Meyers Squibb Company; 2017. Accessed July 12, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009218s118lbl.pdf
no DOI — not checkedUS Department of Health and Human Services; Food and Drug Administration Center; Drug Evaluation and Research (CDER). Guidance for industry: pharmacokinetics in patients with impaired renal function—study design, data analysis, and impact on dosing. Accessed May 4, 2021. https://www.fda.gov/media/78573/download
no DOI — not checked2020 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States
no DOI — not checkedEliquis. Package insert. Bristol-Myers Squibb Company; 2019. Accessed April 19, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202155s024lbl.pdf
no DOI — not checkedXarelto. Package insert. Janssen Pharmaceuticals Inc; 2021. Accessed April 19, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022406s036,202439s036lbl.pdf
no DOI — not checkedPradaxa. Package insert. Boehringer Ingelheim Pharmaceuticals Inc; 2020. Accessed April 19, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022512s039lbl.pdf
no DOI — not checkedSavaysa. Package insert. Daiichi Sankyo Inc; 2020. Accessed April 19, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206316s016lbl.pdf
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-08-10 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1177/10600280211040093"><img src="https://citestamp.com/citestamped/10.1177/10600280211040093/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1177/10600280211040093)